<?xml version='1.0' encoding='utf-8'?>
<document id="25070100"><sentence text="Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects."><entity charOffset="11-19" id="DDI-PubMed.25070100.s1.e0" text="rifampin" /><entity charOffset="24-36" id="DDI-PubMed.25070100.s1.e1" text="ketoconazole" /><entity charOffset="60-72" id="DDI-PubMed.25070100.s1.e2" text="morinidazole" /><pair ddi="false" e1="DDI-PubMed.25070100.s1.e0" e2="DDI-PubMed.25070100.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25070100.s1.e0" e2="DDI-PubMed.25070100.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s1.e0" e2="DDI-PubMed.25070100.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25070100.s1.e1" e2="DDI-PubMed.25070100.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s1.e1" e2="DDI-PubMed.25070100.s1.e2" /></sentence><sentence text="Morinidazole, a 5-nitroimidazole antimicrobial drug, has been approved for the treatment of amoebiasis, trichomoniasis, and anaerobic bacterial infections in China"><entity charOffset="0-12" id="DDI-PubMed.25070100.s2.e0" text="Morinidazole" /><entity charOffset="16-32" id="DDI-PubMed.25070100.s2.e1" text="5-nitroimidazole" /><pair ddi="false" e1="DDI-PubMed.25070100.s2.e0" e2="DDI-PubMed.25070100.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25070100.s2.e0" e2="DDI-PubMed.25070100.s2.e1" /></sentence><sentence text=" It was reported that drug-drug interaction happened after the coadministration of ornidazole, an analog of morinidazole, and rifampin or ketoconazole"><entity charOffset="83-93" id="DDI-PubMed.25070100.s3.e0" text="ornidazole" /><entity charOffset="108-120" id="DDI-PubMed.25070100.s3.e1" text="morinidazole" /><entity charOffset="126-134" id="DDI-PubMed.25070100.s3.e2" text="rifampin" /><entity charOffset="138-150" id="DDI-PubMed.25070100.s3.e3" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25070100.s3.e0" e2="DDI-PubMed.25070100.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25070100.s3.e0" e2="DDI-PubMed.25070100.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s3.e0" e2="DDI-PubMed.25070100.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25070100.s3.e0" e2="DDI-PubMed.25070100.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25070100.s3.e1" e2="DDI-PubMed.25070100.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s3.e1" e2="DDI-PubMed.25070100.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25070100.s3.e1" e2="DDI-PubMed.25070100.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25070100.s3.e2" e2="DDI-PubMed.25070100.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25070100.s3.e2" e2="DDI-PubMed.25070100.s3.e3" /></sentence><sentence text=" Therefore, we measured the plasma pharmacokinetics (PK) of morinidazole and its metabolites in the healthy Chinese volunteers prior to and following the administration of rifampin or ketoconazole using liquid chromatography-tandem mass spectrometry (LC-MS/MS)"><entity charOffset="60-72" id="DDI-PubMed.25070100.s4.e0" text="morinidazole" /><entity charOffset="172-180" id="DDI-PubMed.25070100.s4.e1" text="rifampin" /><entity charOffset="184-196" id="DDI-PubMed.25070100.s4.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25070100.s4.e0" e2="DDI-PubMed.25070100.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25070100.s4.e0" e2="DDI-PubMed.25070100.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s4.e0" e2="DDI-PubMed.25070100.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25070100.s4.e1" e2="DDI-PubMed.25070100.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s4.e1" e2="DDI-PubMed.25070100.s4.e2" /></sentence><sentence text=" The area under the concentration-time curve from time 0 to time t (AUC0-t) and maximum concentration in serum (Cmax) of morinidazole were decreased by 28% and 23%, respectively, after 6 days of exposure to 600 mg of rifampin once daily; the Cmaxs of N(+)-glucuronides were increased by 14%, while their AUC0-ts were hardly changed"><entity charOffset="121-133" id="DDI-PubMed.25070100.s5.e0" text="morinidazole" /><entity charOffset="217-225" id="DDI-PubMed.25070100.s5.e1" text="rifampin" /><entity charOffset="251-268" id="DDI-PubMed.25070100.s5.e2" text="N(+)-glucuronides" /><pair ddi="false" e1="DDI-PubMed.25070100.s5.e0" e2="DDI-PubMed.25070100.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25070100.s5.e0" e2="DDI-PubMed.25070100.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s5.e0" e2="DDI-PubMed.25070100.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25070100.s5.e1" e2="DDI-PubMed.25070100.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s5.e1" e2="DDI-PubMed.25070100.s5.e2" /></sentence><sentence text=" After 7 days of exposure to 200 mg of ketoconazole once daily, the AUC0-t and Cmax of the parent drug were not affected significantly"><entity charOffset="39-51" id="DDI-PubMed.25070100.s6.e0" text="ketoconazole" /></sentence><sentence text=" Cmaxs of N(+)-glucuronides were decreased by 23%; AUC0-ts were decreased by 14%"><entity charOffset="10-27" id="DDI-PubMed.25070100.s7.e0" text="N(+)-glucuronides" /></sentence><sentence text=" The exposure of sulfate conjugate was hardly changed after the coadministration of rifampin or ketoconazole"><entity charOffset="17-24" id="DDI-PubMed.25070100.s8.e0" text="sulfate" /><entity charOffset="84-92" id="DDI-PubMed.25070100.s8.e1" text="rifampin" /><entity charOffset="96-108" id="DDI-PubMed.25070100.s8.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25070100.s8.e0" e2="DDI-PubMed.25070100.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25070100.s8.e0" e2="DDI-PubMed.25070100.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s8.e0" e2="DDI-PubMed.25070100.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25070100.s8.e1" e2="DDI-PubMed.25070100.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s8.e1" e2="DDI-PubMed.25070100.s8.e2" /></sentence><sentence text=" Using recombinant enzyme of UGT1A9 and human hepatocytes, the mechanism of the altered PK behaviors of morinidazole and its metabolites was investigated"><entity charOffset="104-116" id="DDI-PubMed.25070100.s9.e0" text="morinidazole" /></sentence><sentence text=" In human hepatocytes, ketoconazole dose dependently inhibited the formation of N(+)-glucuronides (50% inhibitory concentration [IC50], 1"><entity charOffset="23-35" id="DDI-PubMed.25070100.s10.e0" text="ketoconazole" /><entity charOffset="80-97" id="DDI-PubMed.25070100.s10.e1" text="N(+)-glucuronides" /><pair ddi="false" e1="DDI-PubMed.25070100.s10.e0" e2="DDI-PubMed.25070100.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25070100.s10.e0" e2="DDI-PubMed.25070100.s10.e1" /></sentence><sentence text="5 Î¼M), while rifampin induced the mRNA level of UGT1A9 by 28% and the activity of UGT1A9 by 53%"><entity charOffset="13-21" id="DDI-PubMed.25070100.s11.e0" text="rifampin" /></sentence><sentence text=" In conclusion, the effects of rifampin and ketoconazole on the plasma exposures of morinidazole and N(+)-glucuronide are less than 50%; therefore, rifampin and ketoconazole have little clinical significance in the pharmacokinetics of morinidazole"><entity charOffset="31-39" id="DDI-PubMed.25070100.s12.e0" text="rifampin" /><entity charOffset="44-56" id="DDI-PubMed.25070100.s12.e1" text="ketoconazole" /><entity charOffset="84-96" id="DDI-PubMed.25070100.s12.e2" text="morinidazole" /><entity charOffset="101-117" id="DDI-PubMed.25070100.s12.e3" text="N(+)-glucuronide" /><entity charOffset="148-156" id="DDI-PubMed.25070100.s12.e4" text="rifampin" /><entity charOffset="161-173" id="DDI-PubMed.25070100.s12.e5" text="ketoconazole" /><entity charOffset="235-247" id="DDI-PubMed.25070100.s12.e6" text="morinidazole" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e0" e2="DDI-PubMed.25070100.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e0" e2="DDI-PubMed.25070100.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e0" e2="DDI-PubMed.25070100.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e0" e2="DDI-PubMed.25070100.s12.e3" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e0" e2="DDI-PubMed.25070100.s12.e4" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e0" e2="DDI-PubMed.25070100.s12.e5" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e0" e2="DDI-PubMed.25070100.s12.e6" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e1" e2="DDI-PubMed.25070100.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e1" e2="DDI-PubMed.25070100.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e1" e2="DDI-PubMed.25070100.s12.e3" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e1" e2="DDI-PubMed.25070100.s12.e4" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e1" e2="DDI-PubMed.25070100.s12.e5" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e1" e2="DDI-PubMed.25070100.s12.e6" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e2" e2="DDI-PubMed.25070100.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e2" e2="DDI-PubMed.25070100.s12.e3" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e2" e2="DDI-PubMed.25070100.s12.e4" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e2" e2="DDI-PubMed.25070100.s12.e5" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e2" e2="DDI-PubMed.25070100.s12.e6" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e3" e2="DDI-PubMed.25070100.s12.e3" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e3" e2="DDI-PubMed.25070100.s12.e4" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e3" e2="DDI-PubMed.25070100.s12.e5" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e3" e2="DDI-PubMed.25070100.s12.e6" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e4" e2="DDI-PubMed.25070100.s12.e4" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e4" e2="DDI-PubMed.25070100.s12.e5" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e4" e2="DDI-PubMed.25070100.s12.e6" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e5" e2="DDI-PubMed.25070100.s12.e5" /><pair ddi="false" e1="DDI-PubMed.25070100.s12.e5" e2="DDI-PubMed.25070100.s12.e6" /></sentence><sentence text=" " /></document>